Status:
COMPLETED
Effect of Parenteral Glutamine on Myocardial Injury and Inflammation Biomarkers
Lead Sponsor:
Instituto Mexicano del Seguro Social
Conditions:
Insufficiency;Cardiac
Eligibility:
All Genders
40-70 years
Phase:
NA
Brief Summary
The effect of parenteral glutamine on the biomarkers of myocardial injury and inflammation in patients undergoing cardiac surgery with and without cardiopulmonary bypass (DCP) will be analyzed. Random...
Detailed Description
Introduction: Cardiac surgery is performed in order to improve function and decrease the incidence of cardiac events. The provision of different metabolic substrates before and during cardiac surgery ...
Eligibility Criteria
Inclusion
- Patients with a diagnosis of ischemic heart disease who will undergo surgery to CRC.
- Age 40 to 70 years.
- BMI from 18.5 to 29.9 kg / m2
- Stable renal function with a serum creatinine less than 1.5 mg / dl.
- Complete and signed informed consent.
Exclusion
- Left ventricular ejection fraction \<40%.
- Pre-existing disease such as: Renal impairment under substitute treatment (peritoneal dialysis or hemodialysis), Hepatic impairment, Human immunodeficiency syndrome, Viral liver disease (due to virus B and C).
- Patients with previous cardiac surgery.
- Emergency surgery or myocardial ischemia in progress.
- Known allergy to the supplement to be used in the study
- Alcohol abuse or drug use 1 month before surgery
Key Trial Info
Start Date :
February 4 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 4 2022
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT06065566
Start Date
February 4 2020
End Date
February 4 2022
Last Update
October 4 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Instituto Mexicano del Seguro Social
Guadalajara, Jalisco, Mexico, 44329